Drugs / LP002
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04756934 | Aug 2020 → Aug 2021 | melanoma | Taizhou HoudeAoke Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04755543 | Jun 2019 → Jun 2021 | digestive system neoplasm | Taizhou HoudeAoke Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04600947 | Dec 2020 → May 2022 | primary mediastinal large B-cell lymphoma | Taizhou HoudeAoke Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04740021 | Dec 2020 → Feb 2022 | small cell lung carcinoma | Taizhou HoudeAoke Biomedical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LP002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04756934 ↗ |
| Action | Inhibit | “prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface” NCT04600947 ↗ |
| Modality | Monoclonal antibody | “LP002 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1)” NCT04600947 ↗ |
| Route | Intravenous | “10 mg/kg administered as IV infusion on Day 1 of each 14-day cycle.” NCT04600947 ↗ |